Page 1208 - Hematology_ Basic Principles and Practice ( PDFDrive )

1054.e2 Part VII Hematologic Malignancies

36. Wetzler M, Watson D, Stock W, et al: Autologous transplantation 42. Maude S, Frey N, Shaw P, et al: Chimeric antigen receptor T cells for
for Philadelphia chromosome positive acute lymphoblastic leukemia sustained remissions in leukemia. N Engl J Med 371:1507, 2014.
achieves outcomes similar to allogeneic stem cell transplantation: 43. Park J, Riviere I, Wang X, et al: CD19-Targeted 19-28z CAR Modified
Results of CALGB Study 10001 (Alliance). Haematologica 99:111, Autologous T Cells Induce High Rates of Complete Remission and
2014. Durable Responses in Adult Patients with Relapsed, Refractory B-Cell
37. Ribera JM, Oriol A, Sanz MA, et al: Comparison of the results of ALL. Blood 124(21):Abstract 382, 2014.
the treatment of adolescents and young adults with standard-risk acute 44. Wayne A, Bhojwani D, Richards K, et al: Complete remissions in 3 of 12
lymphoblastic leukemia with the Programa Espanol de Tratamiento en patients with pediatric acute lymphoblastic leukemia (ALL) during phase
Hematologia pediatric-based protocol ALL-96. J Clin Oncol 26:1843, I testing of the anti-CD22 immunotoxin moxetumomab pasudotox.
2008. Blood 116:Abstract 3246, 2010.
38. DeAngelo DJ, Dahlberg S, Silverman LB, et al: A Multicenter Phase 45. Kantarjian H, Thomas D, Jorgensen J, et al: Inotuzumab ozogamicin,
II Study Using a Dose Intensified Pediatric Regimen in Adults with an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute
Untreated Acute Lymphoblastic Leukemia [abstract]. Blood 110:Abstract lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13:403, 2012.
587, 2007. 46. O’Brien S, Thomas D, Jorgensen J, et al: Experience with 2 Dose
39. Stock W, La M, Sanford B, et al: What determines the outcomes for Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in
adolescents and young adults with acute lymphoblastic leukemia treated Refractory-Relapsed Acute Lymphocytic Leukemia (ALL). Blood
on cooperative group protocols? A comparison of Children’s Cancer 120:Abstract 671, 2012.
Group and Cancer and Leukemia Group B studies. Blood 112:1646, 47. Advani A, Stein A, Kantarjian H, et al: A Phase II Study of Weekly
2008. Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive
40. Topp MS, Kufer P, Gokbuget N, et al: Targeted therapy with the T-cell- Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage. Blood
engaging antibody blinatumomab of chemotherapy- refractory minimal 124(21):Abstract 2255, 2014.
residual disease in B-lineage acute lymphoblastic leukemia patients 48. Herrera L, Bostrom B, Gore L, et al: A phase 1 study of Combotox
results in high response rate and prolonged leukemia-free survival. J in pediatric patients with refractory B-lineage acute lymphoblastic
Clin Oncol 29:2493, 2011. leukemia. J Pediatr Hematol Oncol 31:936, 2009.
41. Topp MS, Gökbuget N, Stein AS, et al: Safety and activity of blinatu- 49. Schindler J, Gajavelli S, Ravandi F, et al: A phase I study of a combina-
momab for adult patients with relapsed or refractory B-precursor acute tion of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult
lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. patients with refractory B-lineage acute lymphoblastic leukaemia. Br J
Lancet Oncol 16:57, 2015. Haematol 154:471, 2011.